Atlas Trials

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Clinical trial NCT03409432 · COMPLETED

Trial details

NCT number
NCT03409432
Sponsor
John Reneau
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphomatoid PapulosisPrimary Cutaneous Anaplastic Large Cell LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Cutaneous T-Cell Non-Hodgkin LymphomaStage II Cutaneous T-Cell Non-Hodgkin LymphomaStage III Cutaneous T-Cell Non-Hodgkin LymphomaStage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
Start date
2018-03-16
Primary completion
2025-07-16
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.